Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Videos

Samuel M. Rubinstein, MD, on Relapsed/Refractory Multiple Myeloma: Linvoseltamab Plus Carfilzomib

Samuel M. Rubinstein, MD, on Relapsed/Refractory Multiple Myeloma: Linvoseltamab Plus Bortezomib

Shaji K. Kumar, MD, on Updates on the Treatment Landscape in Multiple Myeloma

Is a Triplet or Quadruplet Regimen More Effective in Managing Newly Diagnosed Multiple Myeloma?

Prashant Kapoor, MD, on New Data on Combination Regimen From Phase III Trial in Multiple Myeloma

Darren Denjay Pan, MD, on Inflammatory Biomarkers as Predictors of Outcomes After CAR T-Cell Therapy for Multiple Myeloma

Ajay K. Nooka, MBBS, Clinical Pearls for Using Elranatamab in Relapsed or Refractory Multiple Myeloma

Ajay K. Nooka, MBBS, on Maintenance Therapy: Benefits Reported in High-Risk Myeloma

Nikhil Munshi, MD, on Using Ciltacabtagene Autoleucel in Treating Relapsed or Refractory Multiple Myeloma: Clinical Considerations

Shaji K. Kumar, MD, on How CAR T-Cell Therapies Are Changing the Therapeutic Landscape in Multiple Myeloma

Jiye Liu, PhD, on Clinical Implications of Findings on KDM6A as a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Francesco Maura, MD, on Clinical Issues: Resistance in Newly Diagnosed Multiple Myeloma Treated With Targeted Immunotherapy

Eileen M. Boyle, MD, PhD, on Predicting Treatment Response With Genomic and Immune Microenvironment Features in Multiple Myeloma

Julie Côté, MD, on Clinical Implications of New Real-World Data on ASCT in Multiple Myeloma

Alexander M. Lesokhin, MD, on Initial Safety Data for Elranatamab in Multiple Myeloma

Paul G. Richardson, MD: A New Era for Patients With Newly Diagnosed Multiple Myeloma?

Tarek H. Mouhieddine, MD, on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies Treatment

Shaji K. Kumar, MD, on Clinical Implications of Changing Treatment Paradigms for Multiple Myeloma

Natalie S. Callander, MD, on Maneuvering the Complex Web of Treatment Options for Multiple Myeloma

Saad Z. Usmani, MBA, MD: Expert Perspective on the Use of Ciltacabtagene Autoleucel in Multiple Myeloma

Nina Shah, MD, on Clinical Implications of Novel Therapies for Multiple Myeloma

Muhamed Baljevic, MD, on Clinical Challenges of Managing Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, on Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone in Multiple Myeloma

Efstathios Kastritis, MD: A New Standard of Care for Amyloidosis in Multiple Myeloma?

Niels van de Donk, MD, PhD, on Early Results on Teclistamab as a Future Treatment Option for Multiple Myeloma

Larry D. Anderson, Jr, MD, PhD, on Idecabtagene Vicleucel CAR T-Cell Therapy in Multiple Myeloma

Taiga Nishihori, MD: Is Maintenance Ixazomab Feasible in High-Risk Myeloma?

Shaji K. Kumar, MD, on Clinical Pearls for Selecting Among Treatments in Multiple Myeloma

Paul G. Richardson, MD, on Treatment Strategies for Newly Diagnosed Multiple Myeloma

Sagar Lonial, MD, on Clinical Implications of New Data on CAR T-Cell Treatments for Multiple Myeloma

Shaji Kumar, MD, and Prashant Kapoor, MD: Update on CAR T-Cell Therapies for Multiple Myeloma

Prashant Kapoor, MD, and Shaji Kumar, MD, on Long-Term Follow-up of Strategies for Upfront Treatment of Multiple Myeloma

Shaji Kumar, MD, and Prashant Kapoor, MD, on BCL2 Inhibition for the Treatment of Resistant Multiple Myeloma

Paul G. Richardson, MD, on a Novel Immunotherapy Plus Dexamethasone in Relapsed or Refractory Myeloma

Prashant Kapoor, MD, and Shaji Kumar, MD, on Bortezomib, Lenalidomide, Dexamethasone With or Without Elotuzumab for Multiple Myeloma

Prashant Kapoor, MD, and Shaji Kumar, MD, on Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma

Shaji Kumar, MD, on Stem Cell Transplant and First-Line Multiple Myeloma Treatment With Bortezomib, Lenalidomide, and Dexamethasone

Mark Bustoros, MD, on Smoldering Myeloma: To Treat or Not to Treat

Edward A. Stadtmauer, MD, on CRISPR-Edited T Cells for Multiple Myeloma

C. Ola Landgren, MD, PhD, on Managing a Complex Four-Agent Regimen in Myeloma

Mark Bustoros, MD, on How to Discuss Preventing or Delaying a Patient’s Treatment

Saad Z. Usmani, MD, on The Challenges of Administering a New Triple Regimen in Myeloma

Nina Shah, MD, on Challenging Treatment Decisions in Multiple Myeloma

Paul G. Richardson, MD, on Using Elotuzumab After Initial Therapy for Multiple Myeloma

Francesca Gay, MD, on Using Elotuzumab to Treat Multiple Myeloma

Sagar Lonial, MD, on Lenalidomide vs Observation Alone in High-Risk Smoldering Multiple Myeloma

Francesca Gay, MD, on the FORTE Trial: Triplet Therapy for Newly Diagnosed Multiple Myeloma

Paul G. Richardson, MD, on a New Triplet Therapy in Relapsed/Refractory Multiple Myeloma

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Administering Daratumumab

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Evolving Treatment Approaches

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Adhering to Ixazomib

Natalie S. Callander, MD, on Using Carfilzomib in Multiple Myeloma

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Shaji K. Kumar, MD, on Multiple Myeloma Treatment: Expert Perspective

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Sagar Lonial, MD, on Multiple Myeloma: Upfront, Relapsed, and Transplant Options

Sarah A. Holstein, MD, PhD, on Multiple Myeloma: New Induction Therapies

Sagar Lonial, MD, on Multiple Myeloma: Managing a Challenging Case

Paul G. Richardson, MD, on Multiple Myeloma: Results From the OPTIMISMM Trial

Patrick J. Kiel, PharmD, BCPS, BCOP, on Treating Multiple Myeloma

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Multiple Myeloma: An Advanced Practitioner’s Perspective

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient's Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

Muzaffar H. Qazilbash, MD, on Multiple Myeloma: Results From a Treatment Trial

David Siegel, MD, PhD, on Relapsed / Refractory Multiple Myeloma: Final Results From the ASPIRE Trial

Adam D. Cohen, MD, on Multiple Myeloma: Findings on CART-BCMA Infusions

Mollie Reed, MSN, RN, ACNP-BC, on Managing Rash Linked to TKIs

Hans C. Lee, MD, on Administering Daratumumab

Kathleen Colson, RN, BSN, BS, on Multiple Myeloma: Managing Treatment-Related Complications

Thomas W. LeBlanc, MD, on Hematologic Malignancies: The Case for Palliative Care

Shaji K. Kumar, MD, on NCCN Multiple Myeloma Guidelines: Process, Evolution, and Clinical Practice

Areej El-Jawahri, MD, on Stem Cell Transplant Survivors: Improving Sexual Function and Quality of Life

Kathleen Colson, RN, BSN, BS, on Preventing Infusion Reactions to Daratumumab

Shaji K. Kumar, MD, on Multiple Myeloma: Management in Those Eligible for Transplant

Natalie S. Callander, MD, on Newly Diagnosed Multiple Myeloma: What Early-Phase Trials Suggest

Noopur S. Raje, MD, and Kenneth C. Anderson, MD, on Myeloma Bone Disease: Denosumab and Zoledronic Acid

Natalie S. Callander, MD, on Multiple Myeloma: Cost Effectiveness of Drugs Used to Treat Relapsed/Refractory Disease

Noopur S. Raje, MD, and Kenneth C. Anderson, MD, on Myeloma Bone: Updated Results on Anti-BCMA CAR T-Cell Therapy

Natalie S. Callander, MD, on Relapsed/Refractory Multiple Myeloma: Expert Perspective on New Research

Kenneth C. Anderson, MD, and Francesca M. Gay, MD, on Newly Diagnosed Multiple Myeloma: Results From the FORTE Trial

The JNCCN Spotlight

Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.